Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Carbon monoxide (CO) is a small, endogenously produced gas that acts as a signaling molecule in the human body. It is primarily generated through the enzymatic degradation of heme by heme oxygenase enzymes. At low physiological levels it plays important roles in vasoregulation and inflammation modulation. CO exerts vasodilatory effects mainly via activation of soluble guanylate cyclase (sGC) and opening potassium channels. The anti-inflammatory effects are attributed to modulation of inflammatory cell signaling and downregulation of pro-inflammatory cytokines. Therapeutic delivery is achieved via Carbon Monoxide-Releasing Molecules (CORMs), compounds that release controlled amounts of CO.
Activation of soluble guanylate cyclase (sGC); Opening potassium channels; Modulation of inflammatory cell signaling; Downregulation of pro-inflammatory cytokines
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Carbon Monoxide Release.